You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
More than 40 percent of women with advanced mismatch repair-deficient endometrial cancer had an objective response to GSK's anti-PD-1 monoclonal antibody.
After surgical resection and two lines of chemotherapy, a patient with serous high-grade endometrial cancer had a complete response to the PARP inhibitor.
The groups have written draft recommendations and are now asking for public comment from pathologists and other stakeholders.
The team analyzed multigene panel test data from Ambry Genetics for 165,000 individuals, focusing on hereditary cancer risk related to 32 genes in six cancer types.
Investigators pooled older and new data from the Prospective Lynch Syndrome Database, tracking outcomes for different mutations across age and gender groups.
Researchers separately found that the assay had high concordance with other techniques in cancers including colorectal and endometrial carcinomas.
A phylogenetic analysis that included multiple samples per patient suggests overlapping driver mutations make their way into multiple metastases in each patient.